Differential binding of disopyramide and warfarin enantiomers to human α1‐acid glycoprotein variants
Aims The F1S and A genetic variants of α1‐acid glycoprotein (AAG) change under various physiological and pathological conditions. They also vary in their drug binding abilities. We have studied the stereoselective binding ability of each of the AAG variants using enantiomers of disopyramide (DP) an...
Gespeichert in:
| Veröffentlicht in: | British journal of clinical pharmacology 2003-12, Vol.56 (6), p.664-669 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 669 |
|---|---|
| container_issue | 6 |
| container_start_page | 664 |
| container_title | British journal of clinical pharmacology |
| container_volume | 56 |
| creator | Nakagawa, T. Kishino, S. Itoh, S. Sugawara, M. Miyazaki, K. |
| description | Aims The F1S and A genetic variants of α1‐acid glycoprotein (AAG) change under various physiological and pathological conditions. They also vary in their drug binding abilities. We have studied the stereoselective binding ability of each of the AAG variants using enantiomers of disopyramide (DP) and warfarin (WR).
Methods The AAG variants were separated by hydroxyapatite chromatography. Binding of drug enantiomers to the AAG variants was studied by the Hummel–Dreyer method. The characteristics of the binding activities were examined by Scatchard plot analysis. The first five amino‐terminal amino acids (residues 112–116) of the cyanogen bromide (CNBr) fragment (residues 112–181) of each of the separated AAG fractions were elucidated by Edman degradation.
Results Commercial AAG was separated into two main fractions. Residues 112–116 of fraction 2 were identical to the amino acid sequences predicted from the AAG A gene, LAFDV, and encode the F1S variant. In fraction 3, the deduced amino acid sequence of the AAG B gene, FGSYL, was established, and encodes the A variant. The binding affinities of both DP enantiomers in fraction 3 were significantly higher than those in fraction 2. The differences between dissociation constants (Kd) in fractions 2 and 3 were 5.2‐fold for (S)‐DP (P |
| doi_str_mv | 10.1046/j.1365-2125.2003.01909.x |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1884290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BCP1909</sourcerecordid><originalsourceid>FETCH-LOGICAL-j3239-740b64cbaf87bf19b7802b080fafa06362fa5e8ddd9aba34d0e4a8f1d9e63aae3</originalsourceid><addsrcrecordid>eNpVkUFu2zAQRYmiQey4uQM3XUoZkhJFLVqgddokgIFkka6JkUjaNCTKoOwk3vUIuUovkkPkJJGSwEFXM8B_84HBI4QySBlk8mydMiHzhDOepxxApMBKKNOHT2R6CD6TKQiQSc5zNiEnfb8GYILJ_JhMWCaZzHgxJctz75yNNmw9NrTywfiwpJ2jxvfdZh-x9cZSDIbeY3QYfaA24EB3rY093XZ0tWsx0Kd_7PnvI9be0GWzr7tN7LZ2gO-GkwHvv5Ajh01vT9_njPz5_et2fpksri-u5j8WyVpwUSZFBpXM6gqdKirHyqpQwCtQ4NAhSCG5w9wqY0yJFYrMgM1QOWZKKwWiFTPy_a13s6taa-rhsYiN3kTfYtzrDr3-Pwl-pZfdnWZKZbyEoeDrewH2NTYuYqh9fyhgeaGUeuW-vXH3vrH7jxz0aEiv9ShCjyL0aEi_GtIP-uf8ZtzEC2nfiv8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Differential binding of disopyramide and warfarin enantiomers to human α1‐acid glycoprotein variants</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Nakagawa, T. ; Kishino, S. ; Itoh, S. ; Sugawara, M. ; Miyazaki, K.</creator><creatorcontrib>Nakagawa, T. ; Kishino, S. ; Itoh, S. ; Sugawara, M. ; Miyazaki, K.</creatorcontrib><description><![CDATA[Aims The F1S and A genetic variants of α1‐acid glycoprotein (AAG) change under various physiological and pathological conditions. They also vary in their drug binding abilities. We have studied the stereoselective binding ability of each of the AAG variants using enantiomers of disopyramide (DP) and warfarin (WR).
Methods The AAG variants were separated by hydroxyapatite chromatography. Binding of drug enantiomers to the AAG variants was studied by the Hummel–Dreyer method. The characteristics of the binding activities were examined by Scatchard plot analysis. The first five amino‐terminal amino acids (residues 112–116) of the cyanogen bromide (CNBr) fragment (residues 112–181) of each of the separated AAG fractions were elucidated by Edman degradation.
Results Commercial AAG was separated into two main fractions. Residues 112–116 of fraction 2 were identical to the amino acid sequences predicted from the AAG A gene, LAFDV, and encode the F1S variant. In fraction 3, the deduced amino acid sequence of the AAG B gene, FGSYL, was established, and encodes the A variant. The binding affinities of both DP enantiomers in fraction 3 were significantly higher than those in fraction 2. The differences between dissociation constants (Kd) in fractions 2 and 3 were 5.2‐fold for (S)‐DP (P < 0.05) and 3.7‐fold for (R)‐DP (P < 0.001). The dissociation constant of (S)‐DP (0.39 ± 0.08 µm) was lower than that of (R)‐DP (0.53 ± 0.10 µm) in fraction 3 [95% confidence interval (CI) − 0.282, − 0.010; P < 0.05], although the binding activities of the DP enantiomers were almost the same in fraction 2. By contrast WR enantiomers had a higher binding affinity in fraction 2 than in fraction 3, the differences in dissociation constants between fractions 2 and 3 being 12.6‐fold for (S)‐WR (P < 0.001) and 8.3‐fold for (R)‐WR (P < 0.001). The dissociation constant of (S)‐WR (0.28 ± 0.10 µm) was significantly lower than that of (R)‐WR (0.48 ± 0.08 µm) in fraction 2 (95% CI − 0.369, − 0.028; P < 0.05), but there were no significant differences between the binding activities of WR enantiomers in fraction 3.
Conclusions DP and WR enantiomers bind preferentially to fraction 3 and fraction 2, respectively. Fractions 2 and 3 are encoded by the AAG A and the AAG B genes, respectively.]]></description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1046/j.1365-2125.2003.01909.x</identifier><identifier>PMID: 14616427</identifier><identifier>CODEN: BCPHBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Biological and medical sciences ; disopyramide ; Drug Disposition ; General pharmacology ; Medical sciences ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments ; stereoselective binding ; variant ; warfarin ; α1‐acid glycoprotein</subject><ispartof>British journal of clinical pharmacology, 2003-12, Vol.56 (6), p.664-669</ispartof><rights>2004 INIST-CNRS</rights><rights>2003 Blackwell Publishing Ltd 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2125.2003.01909.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2125.2003.01909.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15788890$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakagawa, T.</creatorcontrib><creatorcontrib>Kishino, S.</creatorcontrib><creatorcontrib>Itoh, S.</creatorcontrib><creatorcontrib>Sugawara, M.</creatorcontrib><creatorcontrib>Miyazaki, K.</creatorcontrib><title>Differential binding of disopyramide and warfarin enantiomers to human α1‐acid glycoprotein variants</title><title>British journal of clinical pharmacology</title><description><![CDATA[Aims The F1S and A genetic variants of α1‐acid glycoprotein (AAG) change under various physiological and pathological conditions. They also vary in their drug binding abilities. We have studied the stereoselective binding ability of each of the AAG variants using enantiomers of disopyramide (DP) and warfarin (WR).
Methods The AAG variants were separated by hydroxyapatite chromatography. Binding of drug enantiomers to the AAG variants was studied by the Hummel–Dreyer method. The characteristics of the binding activities were examined by Scatchard plot analysis. The first five amino‐terminal amino acids (residues 112–116) of the cyanogen bromide (CNBr) fragment (residues 112–181) of each of the separated AAG fractions were elucidated by Edman degradation.
Results Commercial AAG was separated into two main fractions. Residues 112–116 of fraction 2 were identical to the amino acid sequences predicted from the AAG A gene, LAFDV, and encode the F1S variant. In fraction 3, the deduced amino acid sequence of the AAG B gene, FGSYL, was established, and encodes the A variant. The binding affinities of both DP enantiomers in fraction 3 were significantly higher than those in fraction 2. The differences between dissociation constants (Kd) in fractions 2 and 3 were 5.2‐fold for (S)‐DP (P < 0.05) and 3.7‐fold for (R)‐DP (P < 0.001). The dissociation constant of (S)‐DP (0.39 ± 0.08 µm) was lower than that of (R)‐DP (0.53 ± 0.10 µm) in fraction 3 [95% confidence interval (CI) − 0.282, − 0.010; P < 0.05], although the binding activities of the DP enantiomers were almost the same in fraction 2. By contrast WR enantiomers had a higher binding affinity in fraction 2 than in fraction 3, the differences in dissociation constants between fractions 2 and 3 being 12.6‐fold for (S)‐WR (P < 0.001) and 8.3‐fold for (R)‐WR (P < 0.001). The dissociation constant of (S)‐WR (0.28 ± 0.10 µm) was significantly lower than that of (R)‐WR (0.48 ± 0.08 µm) in fraction 2 (95% CI − 0.369, − 0.028; P < 0.05), but there were no significant differences between the binding activities of WR enantiomers in fraction 3.
Conclusions DP and WR enantiomers bind preferentially to fraction 3 and fraction 2, respectively. Fractions 2 and 3 are encoded by the AAG A and the AAG B genes, respectively.]]></description><subject>Biological and medical sciences</subject><subject>disopyramide</subject><subject>Drug Disposition</subject><subject>General pharmacology</subject><subject>Medical sciences</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><subject>stereoselective binding</subject><subject>variant</subject><subject>warfarin</subject><subject>α1‐acid glycoprotein</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpVkUFu2zAQRYmiQey4uQM3XUoZkhJFLVqgddokgIFkka6JkUjaNCTKoOwk3vUIuUovkkPkJJGSwEFXM8B_84HBI4QySBlk8mydMiHzhDOepxxApMBKKNOHT2R6CD6TKQiQSc5zNiEnfb8GYILJ_JhMWCaZzHgxJctz75yNNmw9NrTywfiwpJ2jxvfdZh-x9cZSDIbeY3QYfaA24EB3rY093XZ0tWsx0Kd_7PnvI9be0GWzr7tN7LZ2gO-GkwHvv5Ajh01vT9_njPz5_et2fpksri-u5j8WyVpwUSZFBpXM6gqdKirHyqpQwCtQ4NAhSCG5w9wqY0yJFYrMgM1QOWZKKwWiFTPy_a13s6taa-rhsYiN3kTfYtzrDr3-Pwl-pZfdnWZKZbyEoeDrewH2NTYuYqh9fyhgeaGUeuW-vXH3vrH7jxz0aEiv9ShCjyL0aEi_GtIP-uf8ZtzEC2nfiv8</recordid><startdate>200312</startdate><enddate>200312</enddate><creator>Nakagawa, T.</creator><creator>Kishino, S.</creator><creator>Itoh, S.</creator><creator>Sugawara, M.</creator><creator>Miyazaki, K.</creator><general>Blackwell Science Ltd</general><general>Blackwell Science</general><general>Blackwell Science Inc</general><scope>IQODW</scope><scope>5PM</scope></search><sort><creationdate>200312</creationdate><title>Differential binding of disopyramide and warfarin enantiomers to human α1‐acid glycoprotein variants</title><author>Nakagawa, T. ; Kishino, S. ; Itoh, S. ; Sugawara, M. ; Miyazaki, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j3239-740b64cbaf87bf19b7802b080fafa06362fa5e8ddd9aba34d0e4a8f1d9e63aae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Biological and medical sciences</topic><topic>disopyramide</topic><topic>Drug Disposition</topic><topic>General pharmacology</topic><topic>Medical sciences</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><topic>stereoselective binding</topic><topic>variant</topic><topic>warfarin</topic><topic>α1‐acid glycoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakagawa, T.</creatorcontrib><creatorcontrib>Kishino, S.</creatorcontrib><creatorcontrib>Itoh, S.</creatorcontrib><creatorcontrib>Sugawara, M.</creatorcontrib><creatorcontrib>Miyazaki, K.</creatorcontrib><collection>Pascal-Francis</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakagawa, T.</au><au>Kishino, S.</au><au>Itoh, S.</au><au>Sugawara, M.</au><au>Miyazaki, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential binding of disopyramide and warfarin enantiomers to human α1‐acid glycoprotein variants</atitle><jtitle>British journal of clinical pharmacology</jtitle><date>2003-12</date><risdate>2003</risdate><volume>56</volume><issue>6</issue><spage>664</spage><epage>669</epage><pages>664-669</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><coden>BCPHBM</coden><abstract><![CDATA[Aims The F1S and A genetic variants of α1‐acid glycoprotein (AAG) change under various physiological and pathological conditions. They also vary in their drug binding abilities. We have studied the stereoselective binding ability of each of the AAG variants using enantiomers of disopyramide (DP) and warfarin (WR).
Methods The AAG variants were separated by hydroxyapatite chromatography. Binding of drug enantiomers to the AAG variants was studied by the Hummel–Dreyer method. The characteristics of the binding activities were examined by Scatchard plot analysis. The first five amino‐terminal amino acids (residues 112–116) of the cyanogen bromide (CNBr) fragment (residues 112–181) of each of the separated AAG fractions were elucidated by Edman degradation.
Results Commercial AAG was separated into two main fractions. Residues 112–116 of fraction 2 were identical to the amino acid sequences predicted from the AAG A gene, LAFDV, and encode the F1S variant. In fraction 3, the deduced amino acid sequence of the AAG B gene, FGSYL, was established, and encodes the A variant. The binding affinities of both DP enantiomers in fraction 3 were significantly higher than those in fraction 2. The differences between dissociation constants (Kd) in fractions 2 and 3 were 5.2‐fold for (S)‐DP (P < 0.05) and 3.7‐fold for (R)‐DP (P < 0.001). The dissociation constant of (S)‐DP (0.39 ± 0.08 µm) was lower than that of (R)‐DP (0.53 ± 0.10 µm) in fraction 3 [95% confidence interval (CI) − 0.282, − 0.010; P < 0.05], although the binding activities of the DP enantiomers were almost the same in fraction 2. By contrast WR enantiomers had a higher binding affinity in fraction 2 than in fraction 3, the differences in dissociation constants between fractions 2 and 3 being 12.6‐fold for (S)‐WR (P < 0.001) and 8.3‐fold for (R)‐WR (P < 0.001). The dissociation constant of (S)‐WR (0.28 ± 0.10 µm) was significantly lower than that of (R)‐WR (0.48 ± 0.08 µm) in fraction 2 (95% CI − 0.369, − 0.028; P < 0.05), but there were no significant differences between the binding activities of WR enantiomers in fraction 3.
Conclusions DP and WR enantiomers bind preferentially to fraction 3 and fraction 2, respectively. Fractions 2 and 3 are encoded by the AAG A and the AAG B genes, respectively.]]></abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>14616427</pmid><doi>10.1046/j.1365-2125.2003.01909.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-5251 |
| ispartof | British journal of clinical pharmacology, 2003-12, Vol.56 (6), p.664-669 |
| issn | 0306-5251 1365-2125 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1884290 |
| source | Wiley Free Content; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Biological and medical sciences disopyramide Drug Disposition General pharmacology Medical sciences Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments stereoselective binding variant warfarin α1‐acid glycoprotein |
| title | Differential binding of disopyramide and warfarin enantiomers to human α1‐acid glycoprotein variants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A50%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20binding%20of%20disopyramide%20and%20warfarin%20enantiomers%20to%20human%20%CE%B11%E2%80%90acid%20glycoprotein%20variants&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Nakagawa,%20T.&rft.date=2003-12&rft.volume=56&rft.issue=6&rft.spage=664&rft.epage=669&rft.pages=664-669&rft.issn=0306-5251&rft.eissn=1365-2125&rft.coden=BCPHBM&rft_id=info:doi/10.1046/j.1365-2125.2003.01909.x&rft_dat=%3Cwiley_pubme%3EBCP1909%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14616427&rfr_iscdi=true |